Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-4099
  • E-ISSN: 1875-6697

Abstract

Background

Astragaloside IV (AS-IV) has been shown to have a curative effect on non-small cell lung cancer (NSCLC). This study aimed to elucidate the role of AS-IV in NSCLC cell anlotinib resistance (AR).

Methods

The NSCLC/AR cells, resistant to anlotinib, have been produced. The role of AS-IV in the AR of NSCLC cells about the miR-181a-3p/unfolded protein response (UPR)-endoplasmic reticulum associated degradation (ERAD) pathway was then discussed by treating the cells with anlotinib or AS-IV, or by manipulating them with inhibitors or mimics of miR-181a-3p, HRD1 or Derlin-1 overexpression plasmids.

Results

We found that AS-IV could suppress the AR of NSCLC cells. In addition, miR-181a-3p was elevated in NSCLC/AR cells. Functionally, AS-IV limited the AR of NSCLC cells by reducing miR-181a-3p. Further, activation of the UPR-ERAD pathway was correlated with AR in NSCLC cells. Increased sensitivity of NSCLC cells to anlotinib caused by miR-181a-3p inhibitor could be reversed by overexpression of HRD1 or Derlin-1.

Conclusion

This research revealed a promising NSCLC/AR treatment approach by showing that AS-IV exposed NSCLC cells to anlotinib by inhibiting the miR-181a-3p/UPR-ERAD axis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cad/10.2174/0115734099252873231117072107
2024-01-17
2025-09-04

  • From This Site

    /content/journals/cad/10.2174/0115734099252873231117072107
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.2149230207593
     [Google Scholar]
  2. SankarK. GadgeelS.M. QinA. Molecular therapeutic targets in non-small cell lung cancer.Expert Rev. Anticancer Ther.202020864766110.1080/14737140.2020.178715632580596
     [Google Scholar]
  3. InamuraK. Update on immunohistochemistry for the diagnosis of lung cancer.Cancers20181037210.3390/cancers1003007229538329
     [Google Scholar]
  4. GridelliC. RossiA. CarboneD.P. GuarizeJ. KarachaliouN. MokT. PetrellaF. SpaggiariL. RosellR. Non-small-cell lung cancer.Nat. Rev. Dis. Primers2015111500910.1038/nrdp.2015.927188576
     [Google Scholar]
  5. HerbstR.S. MorgenszternD. BoshoffC. The biology and management of non-small cell lung cancer.Nature2018553768944645410.1038/nature2518329364287
     [Google Scholar]
  6. DumaN. Santana-DavilaR. MolinaJ.R. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment.Mayo Clin. Proc.20199481623164010.1016/j.mayocp.2019.01.01331378236
     [Google Scholar]
  7. LiangG. MengW. HuangX. ZhuW. YinC. WangC. FassanM. YuY. KudoM. XiaoS. ZhaoC. ZouP. WangY. LiX. CroceC.M. CuiR. miR-196b-5p–mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer.Proc. Natl. Acad. Sci.202011784347435710.1073/pnas.191753111732041891
     [Google Scholar]
  8. HanB. LiK. WangQ. ZhangL. ShiJ. WangZ. ChengY. HeJ. ShiY. ZhaoY. YuH. ZhaoY. ChenW. LuoY. WuL. WangX. PirkerR. NanK. JinF. DongJ. LiB. SunY. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer.JAMA Oncol.20184111569157510.1001/jamaoncol.2018.303930098152
     [Google Scholar]
  9. ZhangJ. WuC. GaoL. DuG. QinX. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects.Adv. Pharmacol.2020878911210.1016/bs.apha.2019.08.00232089240
     [Google Scholar]
  10. RenS. ZhangH. MuY. SunM. LiuP. Pharmacological effects of Astragaloside IV: A literature review.J. Tradit. Chin. Med.201333341341610.1016/S0254‑6272(13)60189‑224024343
     [Google Scholar]
  11. LiL. HouX. XuR. LiuC. TuM. Research review on the pharmacological effects of astragaloside IV.Fundam. Clin. Pharmacol.2017311173610.1111/fcp.1223227567103
     [Google Scholar]
  12. LaiS.T. WangY. PengF. Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy.J. Thorac. Dis.20201273715372410.21037/jtd‑20‑209832802451
     [Google Scholar]
  13. YangC. SunC. LiangX. XieS. HuangJ. LiD. Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer.Cancer Gene Ther.2016234909710.1038/cgt.2016.526964645
     [Google Scholar]
  14. Correia de SousaM. GjorgjievaM. DolickaD. SobolewskiC. FotiM. Deciphering miRNAs’ Action through miRNA Editing.Int. J. Mol. Sci.20192024624910.3390/ijms2024624931835747
     [Google Scholar]
  15. Ali SyedaZ. LangdenS.S.S. MunkhzulC. LeeM. SongS.J. Regulatory mechanism of microRNA expression in cancer.Int. J. Mol. Sci.2020215172310.3390/ijms2105172332138313
     [Google Scholar]
  16. LeeS.S. CheahY.K. The interplay between MicroRNAs and cellular components of Tumour Microenvironment (TME) on Non-Small-Cell Lung Cancer (NSCLC) progression.J. Immunol. Res.2019201911210.1155/2019/304637930944831
     [Google Scholar]
  17. JinX. GuanY. ZhangZ. WangH. Microarray data analysis on gene and miRNA expression to identify biomarkers in non-small cell lung cancer.BMC Cancer202020132910.1186/s12885‑020‑06829‑x32299382
     [Google Scholar]
  18. HuP. MiR-181a reduces radiosensitivity of non-small cell lung cancer via inhibiting PTEN.Panminerva Med.202064337438332506887
     [Google Scholar]
  19. QiuL. ChenW. WuC. YuanY. LiY. Exosomes of oral squamous cell carcinoma cells containing miR-181a-3p induce muscle cell atrophy and apoptosis by transmissible endoplasmic reticulum stress signaling.Biochem. Biophys. Res. Commun.2020533483183710.1016/j.bbrc.2020.09.06632998818
     [Google Scholar]
  20. AlmanzaA. CarlessoA. ChinthaC. CreedicanS. DoultsinosD. LeuzziB. LuísA. McCarthyN. MontibellerL. MoreS. PapaioannouA. PüschelF. SassanoM.L. SkokoJ. AgostinisP. de BellerocheJ. ErikssonL.A. FuldaS. GormanA.M. HealyS. KozlovA. Muñoz-PinedoC. RehmM. ChevetE. SamaliA. Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications.FEBS J.2019286224127810.1111/febs.1460830027602
     [Google Scholar]
  21. PapaioannouA. ChevetE. Driving cancer tumorigenesis and metastasis through uPR signaling.Curr. Top. Microbiol. Immunol.201741415919210.1007/82_2017_3628710693
     [Google Scholar]
  22. JeonY.J. KimT. ParkD. NuovoG.J. RheeS. JoshiP. LeeB.K. JeongJ. SuhS. GrotzkeJ.E. KimS.H. SongJ. SimH. KimY. PengY. JeongY. GarofaloM. ZanesiN. KimJ. LiangG. NakanoI. CresswellP. Nana-SinkamP. CuiR. CroceC.M. miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC.Nat. Commun.201891511010.1038/s41467‑018‑07561‑830504895
     [Google Scholar]
  23. PustovalovaM. AlhaddadL. SmetaninaN. ChigasovaA. BlokhinaT. Chuprov-NetochinR. OsipovA.N. LeonovS. The p53–53BP1-related survival of A549 and H1299 human lung cancer cells after multifractionated radiotherapy demonstrated different response to additional acute X-ray exposure.Int. J. Mol. Sci.2020219334210.3390/ijms2109334232397297
     [Google Scholar]
  24. LuJ. XuW. QianJ. WangS. ZhangB. ZhangL. QiaoR. HuM. ZhaoY. ZhaoX. HanB. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.BMC Med. Genomics201912S23810.1186/s12920‑019‑0482‑y30871526
     [Google Scholar]
  25. LiuW. DuY. WenR. YangM. XuJ. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.Pharmacol. Ther.202020610743810.1016/j.pharmthera.2019.10743831715289
     [Google Scholar]
  26. WangJ. WongY.K. LiaoF. What has traditional Chinese medicine delivered for modern medicine?Expert Rev. Mol. Med.201820e410.1017/erm.2018.329747718
     [Google Scholar]
  27. ZhangA. ZhengY. QueZ. ZhangL. LinS. LeV. LiuJ. TianJ. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.J. Cancer Res. Clin. Oncol.2014140111883189010.1007/s00432‑014‑1744‑x24980548
     [Google Scholar]
  28. YeQ. SuL. ChenD. ZhengW. LiuY. Astragaloside IV induced miR-134 expression reduces EMT and increases chemotherapeutic sensitivity by suppressing CREB1 signaling in colorectal cancer cell line SW-480.Cell. Physiol. Biochem.20174341617162610.1159/00048202529041002
     [Google Scholar]
  29. DaiP.C. LiuD.L. ZhangL. YeJ. WangQ. ZhangH.W. LinX.H. LaiG.X. Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6.Tumour Biol.201739410.1177/101042831769755528443459
     [Google Scholar]
  30. CroceC.M. Causes and consequences of microRNA dysregulation in cancer.Nat. Rev. Genet.2009101070471410.1038/nrg263419763153
     [Google Scholar]
  31. IqbalM.A. AroraS. PrakasamG. CalinG.A. SyedM.A. MicroRNA in lung cancer: Role, mechanisms, pathways and therapeutic relevance.Mol. Aspects Med.20197032010.1016/j.mam.2018.07.00330102929
     [Google Scholar]
  32. PingW. GaoY. FanX. LiW. DengY. FuX. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.Biochem. Biophys. Res. Commun.201849542482248910.1016/j.bbrc.2017.12.09629269300
     [Google Scholar]
  33. GuG. HuC. HuiK. ZhangH. ChenT. ZhangX. JiangX. Exosomal miR-136-5p derived from anlotinib-resistant NSCLC cells confers anlotinib resistance in non-small cell lung cancer through targeting PPP2R2A.Int. J. Nanomed.2021166329634310.2147/IJN.S32172034556984
     [Google Scholar]
  34. AzumiJ. TsubotaT. SakabeT. ShiotaG. miR‐181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF 1 expression.Cancer Sci.201610791256126210.1111/cas.1300627384977
     [Google Scholar]
  35. ClarkeH.J. ChambersJ.E. LinikerE. MarciniakS.J. Endoplasmic reticulum stress in malignancy.Cancer Cell201425556357310.1016/j.ccr.2014.03.01524823636
     [Google Scholar]
  36. WangM. KaufmanR.J. The impact of the endoplasmic reticulum protein-folding environment on cancer development.Nat. Rev. Cancer201414958159710.1038/nrc380025145482
     [Google Scholar]
  37. OlzmannJ.A. KopitoR.R. ChristiansonJ.C. The mammalian endoplasmic reticulum-associated degradation system.Cold Spring Harb. Perspect. Biol.201359a01318510.1101/cshperspect.a01318523232094
     [Google Scholar]
  38. KanekoM. ImaizumiK. SaitoA. KanemotoS. AsadaR. MatsuhisaK. OhtakeY. ER stress and disease: Toward prevention and treatment.Biol. Pharm. Bull.20174091337134310.1248/bpb.b17‑0034228867719
     [Google Scholar]
  39. LiuL. YuL. ZengC. LongH. DuanG. YinG. DaiX. LinZ. E3 ubiquitin ligase HRD1 promotes lung tumorigenesis by promoting sirtuin 2 ubiquitination and degradation.Mol. Cell. Biol.2020407e002571910.1128/MCB.00257‑1931932479
     [Google Scholar]
  40. XuL. WangZ.H. XuD. LinG. LiD.R. WanT. GuoS.L. Expression of Derlin-1 and its effect on expression of autophagy marker genes under endoplasmic reticulum stress in lung cancer cells.Cancer Cell Int.20141415010.1186/1475‑2867‑14‑5024944523
     [Google Scholar]
  41. GaoQ. LiX. XuY. ZhangJ. RongS. QinY. FangJ. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.Cancer Lett.2020476677410.1016/j.canlet.2020.02.00732061752
     [Google Scholar]
/content/journals/cad/10.2174/0115734099252873231117072107
Loading
Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD Axis
Curr. Computeraided Drug Des. 21, 441 (2025); https://doi.org/10.2174/0115734099252873231117072107
/content/journals/cad/10.2174/0115734099252873231117072107
/content/journals/cad/10.2174/0115734099252873231117072107
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anlotinib; Astragaloside IV; ERAD; miR-181a-3p; non-small cell lung cancer; UPR

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test